Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-09-09 06:21Group 1 - Bid Pharma's stock price decreased by 5.26% to 62.38 CNY per share, with a trading volume of 73.24 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 5.669 billion CNY [1] - The company focuses on the front end of new drug research and development, providing innovative drug molecular building blocks and scientific reagents [1] - The main revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - Hongta Hongtu Fund has a significant holding in Bid Pharma, with the Hongta Hongtu Medical Selected Stock Fund A (020331) reducing its position by 157 shares, holding a total of 11,300 shares, which accounts for 5.16% of the fund's net value [2] - The fund has experienced a year-to-date return of 45.4% and a one-year return of 57.15%, ranking 377 out of 4222 and 1498 out of 3798 respectively [2] - The fund manager, Cao Yang, has been in position for 1 year and 363 days, with the fund's total asset size at 12.7543 million CNY and a best return of 44.37% during his tenure [3]